<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03350035</url>
  </required_header>
  <id_info>
    <org_study_id>1042-SE-2001</org_study_id>
    <nct_id>NCT03350035</nct_id>
  </id_info>
  <brief_title>Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus</brief_title>
  <official_title>A Double-Blind Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marinus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marinus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness and safety of an investigational drug, IV
      ganaxolone, as adjunctive therapy to standard of care to treat subjects with status
      epilepticus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo-controlled study to evaluate the safety,
      tolerability, and efficacy of adjunctive IV ganaxolone in subjects with SE.

      Study drug will be added to standard of care before IV anesthetic during the treatment of SE.

      Subjects will be screened for inclusion/exclusion criteria prior to receiving study drug as
      adjunctive therapy by continuous IV. Subject's will be followed up for 3 weeks
      post-treatment.

      Subjects who are known to be at risk for SE may be consented and/or assented prior to an SE
      event.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2018</start_date>
  <completion_date type="Actual">September 18, 2019</completion_date>
  <primary_completion_date type="Actual">September 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind study that will randomize subjects to ganaxolone or placebo in a 1:1 ratio as adjunctive therapy to their standard of care.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome</measure>
    <time_frame>24 hours post study drug initiation</time_frame>
    <description>The number of subjects who didn't require IV anesthetic for SE treatment within the first 24 hours after study drug initiation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Status Epilepticus</condition>
  <condition>Convulsive Status EPILEPTICUS</condition>
  <condition>Non Convulsive Status Epilepticus</condition>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>IV Ganaxolone active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ganaxolone IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Placebo, non-active</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganaxolone</intervention_name>
    <description>IV</description>
    <arm_group_label>IV Ganaxolone active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV</description>
    <arm_group_label>IV Placebo, non-active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects 12 years of age and older

          -  Clinical and/or electrographic seizures

        Exclusion Criteria:

          -  Life expectancy of less than 24 hours

          -  Anoxic brain injury as primary cause of SE

          -  Recent (&lt;24 hour) traumatic brain injury as the primary cause of SE

          -  Administered anesthesia for the treatment of SE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maciej Gasior, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Marinus Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nemours/AI duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oschner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

